相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer
M. E. Lacouture et al.
ANNALS OF ONCOLOGY (2016)
A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options
Hannah R. Wardill et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2016)
Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms
Hannah R. Wardill et al.
MOLECULAR CANCER THERAPEUTICS (2016)
TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea
Hannah R. Wardill et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
Ysabella Z. A. Van Sebille et al.
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE (2016)
In Vitro Infection with Dengue Virus Induces Changes in the Structure and Function of the Mouse Brain Endothelium
Myriam L. Velandia-Romero et al.
PLOS ONE (2016)
ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis
Ysabella Z. A. Van Sebille et al.
CANCER TREATMENT REVIEWS (2015)
Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib
Nagdeep Giri et al.
INVESTIGATIONAL NEW DRUGS (2015)
Determining the mechanisms of lapatinib-induced diarrhoea using a rat model
Joanne M. Bowen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions
Solange Peters et al.
CANCER TREATMENT REVIEWS (2014)
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial
Suresh S. Ramalingam et al.
LANCET ONCOLOGY (2014)
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
A. R. Abdul Razak et al.
ANNALS OF ONCOLOGY (2013)
Mechanisms of TKI-induced diarrhea in cancer patients
Joanne M. Bowen
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE (2013)
Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea
Joanne M. Bowen et al.
CANCER BIOLOGY & THERAPY (2012)
Irinotecan Injures Tight Junction and Causes Bacterial Translocation in Rat
Toshihiro Nakao et al.
JOURNAL OF SURGICAL RESEARCH (2012)
Heparin-binding EGF-like growth factor protects intestinal stem cells from injury in a rat model of necrotizing enterocolitis
Chun-Liang Chen et al.
LABORATORY INVESTIGATION (2012)
Tumor control versus adverse events with targeted anticancer therapies
Dorothy M. K. Keefe et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
The Intestinotrophic Peptide, GLP-2, Counteracts the Gastrointestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, and Cisplatin
Andreas Rosen Rasmussen et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
ErbB Signaling Is Required for the Proliferative Actions of GLP-2 in the Murine Gut
Bernardo Yusta et al.
GASTROENTEROLOGY (2009)
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy
Yohann Loriot et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis
Richard M. Logan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
Jeffrey A. Engelman et al.
CANCER RESEARCH (2007)
The intestinotrophic peptide, GLP-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib
Kristine Juul Hare et al.
CLINICAL CANCER RESEARCH (2007)
Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage
Joanne M. Bowen et al.
SUPPORTIVE CARE IN CANCER (2006)
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer
RJ Gibson et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2003)
Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats
J Berlanga-Acosta et al.
GUT (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans
DMK Keefe et al.
GUT (2000)
分享论文
